GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Cash Payments

CRISPR Therapeutics AG (LTS:0VRQ) Cash Payments


View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

CRISPR Therapeutics AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Cash Payments
Comparable Companies
AKRO RARE PTCT SWTX VKTX ADMA ZLAB BHVN RNA RXRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
CRSP:USA CRSP:Mexico
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Website
https://www.crisprtx.com
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.